Ask AI
ProCE Banner Activity

Precision in Progress: Advancing Personalized Care in EGFR Mutation–Positive NSCLC Care

Slideset

View these downloadable slides as a resource that accompanies the educational program on EGFR mutations in the treatment of NSCLC. 

Released: March 11, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Taiho Oncology, Inc.

Taiho Oncology, Inc.

Target Audience

This activity is intended for medical oncologists, pulmonologists, and other healthcare professionals caring for patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply clinical trial evidence to guide the personalized use of EGFR-targeted monotherapies, combinations, and antibody–drug conjugates across the EGFRm NSCLC disease continuum, including post-progression and earlier stages of disease

  • Assess and mitigate adverse events associated with novel EGFR-directed therapies using evidence-based management strategies to optimize adherence and quality of life

  • Integrate patient-specific factors—including molecular resistance patterns, prior treatment exposure, comorbidities, and preferences—into individualized treatment planning for EGFRm NSCLC

  • Evaluate the latest evidence on emerging agents and combinations for patients with EGFR Exon 20 mutation-positive NSCLC